Pfizer Inc. Chief Executive Officer Albert Bourla said he’ll do “whatever it takes” to keep profits growing, including ...

Unverified data about events after vaccinations is not evidence that the vaccine caused the event, as suggested in social ...

Pfizer's 14% operational growth in non-COVID products shows the core business is stronger than many believe. The company's ...

Raining on the parade even more, Pfizer just reported some good news that seems to confirm the presence of some internal issues. So let's examine this new green flag that's also a red flag for anyone ...

Pfizer’s revenue from pharmaceuticals declined Pharmaceutical giant Pfizer is getting into the health care delivery business.

With the total return of Pfizer's (NYSE: PFE) shares rising by just 1.9% this year so far, investors may be yearning for some ...

Pfizer now expects between $61 billion and $64 billion in revenue for the year and raised its outlook for adjusted earnings ...

Company CEO Albert Bourla said Pfizer would consider “any good ideas” that create value, but argued it has already made ...

Pfizer reported an adjusted EPS of $1.06, exceeding estimates by over 72%. Revenue reached $17.7 billion, marking a 32% year ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Pfizer (PFE – Research Report) today. The company’s shares ...

The pharmaceutical company reported its third consecutive quarter with positive results.